Lubo Ivanko/iStock Editorial via Getty Images Gilead Sciences (NASDAQ:GILD) has dropped 15% YTD substantially underperforming the market. We last discussed the company two months, discussing how it was turning itself around. The company was impacted by tough trial results from Trodelvy, another disappointment given the more than $20 billion acquisition of Immunomedics. Despite that, the company has the ability to utilize its assets to generate strong returns while supporting a >4% yield. Gilead Sciences ...